Share Prices & Company Research

Stockbroking

Oxford Biodynamics

Current Price 92.00p Bid 90.00p Ask 97.00p Change -5.08%
Last Updated: 21/09/2019 13:57. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Oxford BioDynamics plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company's award-winning, proprietary technology platform, EpiSwitch, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. In particular, EpiSwitch can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Financial Highlights Year Ended 30/09/2018

Turnover
£1.19m
Operating Profit
£-2.60m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-44.77

Key Personnel

Christian Gurth Hoyer-Millar
Chief Executive Officer
Paul Leslie Stockdale
Chief Financial Officer
Dr Alexandre Akoulitchev
Chief Scientific Officer
Stephen Charles Diggle
Non-Executive Chairman
Dr Peter Pack
Non-Executive Director
Dr David Mark Anthony Holbrook
Non-Executive Director

Stock Details

EPIC
OBD
ISIN
GB00BD5H8572
Shares in Issue
92,559,771
Market cap
£91.17m
Sector

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
93.50p
Bid Price
90.00p
Ask Price
97.00p
Volume
20140
Change Today
-5.00p
% Change Today
-5.08%
Open
96.00p
Previous Close
93.50p
Intraday High
96.00p
Intraday Low
90.00p
52 Week High
226.00p
52 Week Low
80.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Oxford Biodynamics Intra-day Chart

Oxford Biodynamics News

News in this section is provided by AJ Bell

Director Deals - Oxford Biodynamics Plc (OBD) 12 Sep 2019 | 14:05 Director Deals - Oxford Biodynamics Plc (OBD) 10 Sep 2019 | 12:45 Director Deals - Oxford Biodynamics Plc (OBD) 09 Sep 2019 | 13:25 Director Deals - Oxford Biodynamics Plc (OBD) 06 Sep 2019 | 15:10 Director Deals - Oxford Biodynamics Plc (OBD) 03 Sep 2019 | 10:10 Director Deals - Oxford Biodynamics Plc (OBD) 02 Sep 2019 | 11:45 Director Deals - Oxford Biodynamics Plc (OBD) 02 Sep 2019 | 11:45 Director Deals - Oxford Biodynamics Plc (OBD) 29 Aug 2019 | 17:00 Director Deals - Oxford Biodynamics Plc (OBD) 28 Aug 2019 | 11:05 Director Deals - Oxford Biodynamics Plc (OBD) 15 Aug 2019 | 12:00 Director Deals - Oxford Biodynamics Plc (OBD) 14 Aug 2019 | 14:20 Director Deals - Oxford Biodynamics Plc (OBD) 05 Aug 2019 | 13:50 Director Deals - Oxford Biodynamics Plc (OBD) 01 Aug 2019 | 10:20 Director Deals - Oxford Biodynamics Plc (OBD) 26 Jul 2019 | 15:25 Oxford BioDynamics to present four papers at Kuala Lumpur conference 19 Jul 2019 | 07:52 Director Deals - Oxford Biodynamics Plc (OBD) 09 Jul 2019 | 09:00 Director Deals - Oxford Biodynamics Plc (OBD) 09 Jul 2019 | 09:00 Director Deals - Oxford Biodynamics Plc (OBD) 09 Jul 2019 | 09:00 Director Deals - Oxford Biodynamics Plc (OBD) 06 Jun 2019 | 15:20 Oxford BioDynamics posts first-half loss as expenses offset rising sales 28 May 2019 | 08:30 Oxford BioDynamics to present at Shanghai conference 08 May 2019 | 09:07 Oxford BioDynamics joins US study to identify sclerosis biomarkers 03 May 2019 | 14:50 Oxford BioDynamics wins UK award for biomarker technology 23 Apr 2019 | 07:51 Oxford BioDynamics to participate in UK prostate cancer screening trial 19 Mar 2019 | 09:53 Director Deals - Oxford Biodynamics Plc (OBD) 15 Feb 2019 | 13:50 Oxford BioDynamics chairman David Williams to stand down 11 Jan 2019 | 08:24 Oxford BioDynamics books annual loss amid flat sales, rising costs 11 Dec 2018 | 07:34 Oxford BioDynamics forms autism research pact in Italy 12 Nov 2018 | 09:28

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
30 Sep 2018
30 Sep 2017
Tangible Assets
1.0
0.8
Intangible Assets & Goodwill
0.4
0.0
Investments & Other Non-Current Assets
0.0
0.0
Total Non-Current Assets
1.3
0.8
Inventory
0.2
0.1
Trade & Receivables
1.2
1.0
Cash & Receivables
18.3
10.8
Other Current Assets & Assets Held for Resale
0.0
0.0
Total Assets
20.9
12.7

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
30 Sep 2018
30 Sep 2017
Short Term Liabilities
0.8
1.0
Long Term Liabilities
0.1
0.1
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
0.9
1.1

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
30 Sep 2018
30 Sep 2017
Net Assets
20.1
11.6

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
30 Sep 2018
30 Sep 2017
Share Capital
0.9
0.9
Minority Interests
0.0
0.0
Retained Earnings
-0.5
0.4
Share Premium Account
16.7
6.5
Other Equity
2.9
3.8
Total Equity
20.1
11.6

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
30 Sep 2018
30 Sep 2017
Cashflow from Operating Activities
-1.9
-1.5
Cashflow Before Financing
-2.6
-1.9
Increase / Decrease in Cash
7.4
3.6

Income (£m)

Data has been provided by AJ Bell

Reporting Date
30 Sep 2018
30 Sep 2017
Turnover
1.2
1.2
Cost of Sales
0.0
0.0
Gross Profit
0.0
0.0
Operating Profit
-2.6
-4.0
Pre-Tax Profit
-2.4
-4.0
Profit / Loss for the Year
-2.0
-3.8
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.